Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT07252232
Recruiting Phase 3

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07252232 · tracked via the Priya Life Science South Korea tracker
Sponsor
Revolution Medicines, Inc
Phase
Phase 3
Started
2025-12-15
Last updated
2026-09-23

Condition(s) studied

Pancreatic CancerPDACPDAC - Pancreatic Ductal AdenocarcinomaResectable Pancreatic Ductal Adenocarcinoma (PDAC)Resected Pancreatic Adenocarcinoma

Investigational drug(s) / intervention(s)

daraxonrasib →

daraxonrasib: oral tablets

Study summary

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * At least 18 years old and has provided informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Histologically confirmed PDAC with successful (R0/R1) curative intent surgical resection and no evidence of recurrent or metastatic disease. * Must have received perioperative (neoadjuvant, adjuvant, or a combination of both) multi-agent chemotherapy. * Must have completed most recent treatment within the past 12 weeks. * Adequate organ function (bone marrow, liver, kidney, coagulation). * Documented RAS mutation status. * Able to take oral medications. Exclusion Criteria: * Prior therapy with direct RAS-targeted therapy (eg. degraders and/or inhibitors). * Any conditions that may affect the ability to take or absorb study drug. * Major surgery within 28 days prior to randomization. * Patient is unable or unwilling to comply with protocol-required study visits or procedures.

Primary outcome measure(s)

  • Disease-Free Survival (DFS) per Investigator — Up to approximately 5 years
    DFS defined as the time from randomization until disease recurrence or death from any cause, whichever occurs first. Recurrence is per response evaluation criteria in solid tumors (RECIST) v1.1 as assessed by Investigator.

Trial sites (78)

FacilityCityRegionStatus
Mayo Clinic Phoenix Arizona Recruiting
HonorHealth Research Institute Scottsdale Arizona Recruiting
UC San Diego Moores Cancer Center La Jolla California Recruiting
Cedars-Sinai Cancer at Cedars-Sinai Medical Center Los Angeles California Recruiting
University of California, Los Angeles Los Angeles California Recruiting
Stanford Cancer Institute Palo Alto California Recruiting
University of California, Davis Comprehensive Cancer Center Sacramento California Recruiting
University of California, San Francisco San Francisco California Recruiting
Rocky Mountain Cancer Centers, LLP Lakewood Colorado Recruiting
Hartford Healthcare Hartford Connecticut Recruiting
Mayo Clinic Jacksonville Florida Recruiting
University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center Miami Florida Recruiting
Florida Cancer Specialists St. Petersburg Florida Recruiting
Piedmont Physicians Medical Oncology Atlanta Atlanta Georgia Recruiting
Winship Cancer Institute, Emory University Atlanta Georgia Recruiting
Community Health Network Indianapolis Indiana Recruiting
University of Kansas Medical Center Research Institute, Inc. Lawrence Kansas Recruiting
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins & Sibley Memorial Hospital Baltimore Maryland Recruiting
Massachusetts General Hospital Boston Massachusetts Recruiting
Dana Farber Cancer Institute (DFCI) Boston Massachusetts Recruiting
Mayo Clinic Cancer Center Rochester Minnesota Recruiting
Saint Luke's Cancer Institute Kansas City Missouri Recruiting
University of Nebraska Medical Center Omaha Nebraska Recruiting
Comprehensive Cancer Centers of Nevada Las Vegas Nevada Recruiting
Laura and Issac Perlmutter Cancer Center at NYU Langone-Ambulatory Care Center New York New York Recruiting
Icahn School of Medicine at Mount Sinai New York New York Recruiting
Columbia University Medical Center New York New York Recruiting
Memorial Sloan Kettering Cancer Center New York New York Recruiting
University of Rochester Medical Center Rochester New York Recruiting
Duke Cancer Center Durham North Carolina Recruiting
Taylor Cancer Research Center Maumee Ohio Recruiting
University of Pennsylvania, Abramson Cancer Center Philadelphia Pennsylvania Recruiting
UPMC Hillman Cancer Center Pittsburgh Pennsylvania Recruiting
Avera Cancer Institute Sioux Falls South Dakota Recruiting
SCRI Oncology Partners Nashville Tennessee Recruiting
Texas Oncology - DFW Dallas Texas Recruiting
University of Texas, Southwestern Medical Center Dallas Texas Recruiting
University of Texas MD Anderson Cancer Center Houston Texas Not Yet Recruiting
Texas Oncology - Northeast Texas Longview Texas Recruiting
University of Utah, Huntsman Cancer Institute Salt Lake City Utah Recruiting

+ 38 more sites — see the full list on the official registry below.

More Revolution Medicines, Inc. trials in South Korea

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) Recruiting
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors Active, not recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Recruiting

Other trials for the same condition

A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma Recruiting
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) Active, not recruiting
Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer Starting soon
Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer Active, not recruiting
ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07252232 on ClinicalTrials.gov ↗ ← All trials in South Korea